Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation/accessibility of Resmetirom
Paul Brennan, Christopher J. Kopka, Leire Agirre‐Garrido, Camila Dalby Hansen, Naim Alkhouri, Jörn M. Schattenberg, Dana Ivancovsky‐Wajcman, Scott Isaacs, Maurice Stephan Michel, Jeffrey V. Lazarus
Abstract
Around 5.3% of adults worldwide are living with metabolic dysfunction-associated steatohepatitis (MASH). As liver fibrosis develops, their incidence of cirrhosis, hepatocellular carcinoma, cardiovascular complications, and non-liver cancer increases. We analyse MAESTRO-NASH resmetirom data and discuss real-world implications following approval. US-based patients now have a novel treatment and expert use recommendations. We anticipate that the UK and EU will approve resmetirom; however, questions remain regarding patient selection and implementation practice.